Sublingual administration of warfarin: a novel form of delivery

Abstract

Current therapy for venous thromboembolism (VTE) includes the initiation of short acting parenteral agents, heparin, low-molecular-weight heparin, or fondaparinux, with subsequent conversion to oral warfarin therapy for the duration of anticoagulation. We present two patients who required long-term anticoagulation for VTE but because of gastrointestinal dysmotility issues were unable to use standard oral anticoagulation. Warfarin is water soluble and absorbed across the epithelium; therefore, we elected to administer warfarin sublingually in an effort to avoid the dysmotility issues while trying to achieve therapeutic anticoagulation. Using sublingual warfarin dosing we were able to achieve therapeutic anticoagulation without complications. Both patients required approximately 6 days to achieve a therapeutic International Normalized Ratio (INR). Neither patient reported adverse side effects related to the sublingual dosing. This unique form of warfarin delivery may be considered for patients with gastrointestinal dysmotility or other gastrointestinal issues which prevent oral use of medications.

Keywords

anticoagulation catheter-related thrombosis deep venous thrombosis pharmacology venous thromboembolism warfarin

References

1 Anderson FA Zayaruzny M Heit JA Fidan D Cohen AT . Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777–782.

2 Silverstein MD Heit JA Mohr DN . Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–593.

3 Buller HR Agnelli G Hull RD . Antithrombotic therapy for venous thromboembolic disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S–428S.

4 Kucher N Quiroz R McKean S Sasahara AA Goldhaber SZ . Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 2005; 10: 251–256.

5 Dinwoodey DL Ansell JE . Heparins, low-molecular-weight heparins, and pentasaccharides. Clin Geriatr Med 2006; 22: 1–15.

6 Jacobs BR . Central venous catheter occlusion and thrombosis. Crit Care Clin 2003; 19: 489–514.

7 Van Rooden CJ Tesselaar MET Osanto S Rosendaal FR Huisman MV . Deep vein thrombosis associated with central venous catheters – a review. J Thromb Haemost 2005; 3: 2409–2419.

8 Warkentin TE Maurer BT Aster RH . Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356: 2653–2655.

9 Ansell J Hirsch J Poller L Bussey H Jacobson A Hylek E . The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 204S–233S.